Extract

The primary objective of this trial is to study the efficacy of oxycodone/naloxone prolonged release tablets (OXN PR), compared to oxycodone prolonged release tablets (Oxy PR), for the reduction of the intensity of opioid-induced constipation symptoms in patients treated for cancer or non-cancer pain.

Inclusion criteria

• For both compounds, treatment for cancer or non-cancer pain, adult subjects with a diagnosis of cancer pain or non-cancer pain such as chronic low back pain, osteoarthritis or other. Only for targinact, the intention of naloxone is to reduce the intensity of opioid-induced constipation symptoms

Links

• euctr
• ictrp